Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q2 CY2026, with sales up 13% year on year to $12.59 billion. Its non-GAAP profit of $1.31 per share was 2.6% above analysts’ ...

Abbott Laboratories (NYSE:ABT) plans to separate its Nutrition segment into an independent publicly traded company, targeting ...

Abbott Laboratories has seen a mixed share price record in recent years, which raises a straightforward question for anyone ...

Abbott Laboratories (ABT) delivered a strong Q2 2026 performance that surprised Wall Street, with the healthcare giant posting a double beat on both top and bottom lines on July 16, 2026. The earnings ...

Abbott Laboratories remains a Buy, driven by robust device and diagnostics growth and the strategic spin-off of its Nutrition ...

Wall Street still prices Abbott like a slow-and-steady dividend stalwart, but a pair of massive strategic moves beneath the surface suggests that framing may be costing investors a significant ...

Abbott, which also makes diagnostics and medical devices, will spin off the unit that makes Similac and Ensure into its own ...

Abbott's second-quarter 2026 earnings gave investors a good reason to be bullish. Sales rose 13% to about $12.6 billion, while adjusted earnings per share (EPS) rose to $1.31. The healthcare company ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q3 2026, with sales up 14.5% year on year to $13.01 ...

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Healthcare product and device company Abbott ...